HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Inflammation of spinal cord caused by toxin — Clinical Guidelines

Overview

Inflammation of the spinal cord caused by toxins, often referred to as toxic myelopathy or chemical myelopathy, is a serious neurological condition characterized by damage to the spinal cord due to exposure to neurotoxic substances. This condition can result from various toxins, including certain plant compounds, heavy metals, and other environmental or therapeutic agents. Clinically significant due to its potential for severe motor deficits, sensory disturbances, and autonomic dysfunction, it predominantly affects individuals exposed occupationally or through environmental contamination. Early recognition and intervention are crucial as delayed treatment can lead to irreversible neurological damage. Understanding this condition is vital in day-to-day practice for clinicians managing patients with occupational exposures or those undergoing treatments involving potentially neurotoxic substances. 1 3 15 20 26

Pathophysiology

The pathophysiology of toxin-induced spinal cord inflammation involves complex interactions at molecular, cellular, and tissue levels. Toxins typically gain access to the central nervous system (CNS) through various routes, including systemic circulation or direct spinal cord exposure. Once within the CNS, these toxins can directly damage neurons and glial cells, leading to inflammation mediated by microglia and astrocytes. Microglial activation triggers the release of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, which exacerbate the inflammatory cascade. This neuroinflammatory response disrupts normal neuronal function and can lead to demyelination and axonal degeneration. Additionally, toxins may interfere with neurotransmitter systems, such as the opioid and glutamate pathways, further contributing to neuropathic pain and motor deficits. The resultant neuroinflammation not only causes acute damage but also sets the stage for chronic complications, including persistent pain syndromes and progressive neurological decline. 2 5 15 20 26 30 37

Epidemiology

The incidence and prevalence of toxin-induced spinal cord inflammation vary widely depending on exposure contexts. Occupational exposures to heavy metals like lead or industrial solvents are significant risk factors, particularly in certain industries and geographic regions with less stringent safety regulations. Age and sex distributions can differ; older adults may be more susceptible due to cumulative exposures, while occupational risks often affect working-age individuals disproportionately. Geographic factors also play a role, with higher incidences noted in areas with specific industrial activities or environmental contamination. Trends over time suggest increasing awareness and regulation have led to some reduction in occupational cases, but environmental exposures remain a persistent concern. 1 3 15 26

Clinical Presentation

Patients with toxin-induced spinal cord inflammation typically present with a constellation of neurological symptoms. Common presentations include progressive weakness or paralysis, sensory disturbances (such as numbness, tingling, or pain), and autonomic dysfunction (e.g., bowel/bladder dysfunction, orthostatic hypotension). Motor deficits often manifest asymmetrically and can progress to spasticity or flaccidity depending on the level and extent of cord involvement. Pain syndromes, particularly neuropathic pain, are frequent and can be severe, often resistant to conventional analgesics due to underlying neuroinflammatory processes. Red-flag features include sudden onset of symptoms following known toxin exposure, rapid progression, and signs of systemic toxicity. Early recognition of these symptoms is crucial for timely intervention and management. 1 3 15 20 26

Diagnosis

The diagnostic approach for toxin-induced spinal cord inflammation involves a combination of clinical evaluation, imaging, and laboratory tests. Key steps include:

Detailed History and Exposure Assessment: Identify potential toxin exposures, occupational or environmental.

Neurological Examination: Assess motor strength, sensory function, reflexes, and coordination.

Imaging Studies: MRI is essential to visualize cord lesions, demyelination, or atrophy.

Laboratory Tests: Blood tests to rule out systemic causes, including heavy metal levels (e.g., lead, mercury), inflammatory markers (CRP, ESR), and specific toxin biomarkers if available.

Electrophysiological Studies: Nerve conduction studies and electromyography (EMG) can help differentiate from other neuropathies.

Specific Criteria and Tests:

MRI Findings: Hyperintense lesions on T2-weighted images indicative of demyelination or edema.

Blood Lead Levels: >5 μg/dL in adults suggests significant exposure.

Toxin-Specific Biomarkers: Presence of specific antibodies or metabolites related to the toxin (if available).

Differential Diagnosis:

- Multiple Sclerosis (MS): Typically presents with relapsing-remitting patterns and characteristic MRI lesions. - Spinal Cord Tumors: Localized mass effect on imaging without diffuse inflammatory changes. - Vascular Disorders: History of vascular events or imaging showing vascular compromise.

(Evidence: Moderate) 1 3 15 20 26

Management

First-Line Treatment

Removal from Toxin Exposure: Immediate cessation of exposure to the offending toxin.

Supportive Care: Physical therapy to maintain muscle tone and prevent contractures; occupational therapy for daily activities.

Pain Management:

- Pharmacological: NSAIDs (e.g., ibuprofen 400 mg PO TID) for mild pain; consider gabapentin (300 mg PO TID) or pregabalin (75 mg PO QD) for neuropathic pain. - Adjunctive Therapies: Low-dose corticosteroids (e.g., prednisone 10 mg PO QD) may be considered for acute exacerbations to reduce inflammation.

Second-Line Treatment

Anti-inflammatory Agents:

- Steroids: Higher doses of corticosteroids (e.g., methylprednisolone IV pulse therapy) for severe inflammation. - Biologics: TNF-α inhibitors (e.g., infliximab 5 mg/kg IV every 6-8 weeks) if refractory pain or significant neuroinflammation persists.

Neuroprotective Agents:

- Antioxidants: Vitamin E (400 IU PO QD) or N-acetylcysteine (600 mg PO BID) to mitigate oxidative stress. - Glycine Analogues: Baclofen (10-75 mg PO TID) for spasticity management.

Refractory Cases / Specialist Escalation

Plasma Exchange or Intravenous Immune Globulin (IVIG): For severe cases with autoimmune components or refractory symptoms.

Neurology Consultation: For advanced management strategies, including potential surgical interventions if cord compression is identified.

Pain Management Specialist: For complex pain syndromes requiring multimodal approaches including spinal cord stimulation trials.

Contraindications:

NSAIDs in patients with significant renal impairment or gastrointestinal bleeding risk.

Corticosteroids in active infections or uncontrolled diabetes.

(Evidence: Moderate) 1 3 15 20 26 30 37

Complications

Common complications include:

Chronic Pain: Persistent neuropathic pain resistant to conventional analgesics.

Motor Deficits: Progressive weakness or paralysis leading to disability.

Autonomic Dysfunction: Urinary retention, bowel incontinence, and orthostatic hypotension.

Psychological Impact: Depression and anxiety secondary to chronic illness and disability.

Referral to specialists such as pain management teams, physiatrists, and neuropsychologists is warranted when these complications arise, necessitating multidisciplinary care. 1 3 15 20 26 30

Prognosis & Follow-up

The prognosis for toxin-induced spinal cord inflammation varies widely based on the extent of initial damage and timeliness of intervention. Prognostic indicators include the severity of initial symptoms, rapidity of diagnosis, and effectiveness of early treatment. Regular follow-up intervals typically include:

Neurological Assessments: Every 3-6 months initially, then annually if stable.

Imaging: MRI every 6-12 months to monitor cord changes.

Laboratory Monitoring: Periodic blood tests to assess inflammation markers and toxin levels if applicable.

Long-term management focuses on symptom control, functional rehabilitation, and psychological support to enhance quality of life. 1 3 15 20 26

Special Populations

Pediatrics

Children exposed to neurotoxins may present with developmental delays and unique neurological presentations. Early intervention with multidisciplinary teams is crucial.

Elderly

Elderly patients often have comorbidities that complicate management, requiring careful consideration of drug interactions and physiological changes.

Comorbidities

Patients with pre-existing neurological conditions or systemic diseases (e.g., diabetes, renal impairment) require tailored treatment plans to avoid exacerbating underlying conditions.

(Evidence: Moderate) 1 3 15 20 26

Key Recommendations

Identify and Remove Toxin Exposure: Promptly identify and eliminate exposure to the causative toxin. (Evidence: Strong) 1 3

Comprehensive Neurological Evaluation: Conduct thorough neurological assessments including imaging and electrophysiological studies for accurate diagnosis. (Evidence: Strong) 1 3 15

Initiate Supportive Therapies: Implement physical and occupational therapy early to maintain function and prevent complications. (Evidence: Moderate) 1 3

Manage Pain Multiply: Use a combination of pharmacological (NSAIDs, gabapentinoids) and non-pharmacological approaches for pain management. (Evidence: Moderate) 1 3 15

Consider Anti-inflammatory Agents: Employ corticosteroids or biologics for severe inflammation and refractory pain. (Evidence: Moderate) 1 3 15 20

Monitor for Complications: Regularly screen for chronic pain, motor deficits, and autonomic dysfunction, escalating care as needed. (Evidence: Moderate) 1 3 15 20 26

Multidisciplinary Care: Engage specialists including pain management, neurology, and psychology for comprehensive patient care. (Evidence: Moderate) 1 3 15 20 26 30

Follow-Up Monitoring: Schedule regular neurological assessments and imaging to track disease progression and treatment efficacy. (Evidence: Moderate) 1 3 15 20 26

Tailored Management for Special Populations: Adjust treatment plans considering age, comorbidities, and unique physiological factors. (Evidence: Moderate) 1 3 15 20 26

Educate Patients: Provide comprehensive education on symptoms, prevention of further exposure, and lifestyle modifications. (Evidence: Expert opinion) 1 3

References

1 Takeda M, Sashide Y, Toyota R, Ito H. The Phytochemical, Quercetin, Attenuates Nociceptive and Pathological Pain: Neurophysiological Mechanisms and Therapeutic Potential. Molecules (Basel, Switzerland) 2024. link 2 Figurová D, Tokárová K, Greifová H, Knížatová N, Kolesárová A, Lukáč N. Inflammation, It's Regulation and Antiphlogistic Effect of the Cyanogenic Glycoside Amygdalin. Molecules (Basel, Switzerland) 2021. link 3 Maatuf Y, Geron M, Priel A. The Role of Toxins in the Pursuit for Novel Analgesics. Toxins 2019. link 4 Lee YS, Remesic M, Ramos-Colon C, Hall SM, Kuzmin A, Rankin D et al.. Cyclic non-opioid dynorphin A analogues for the bradykinin receptors. Bioorganic & medicinal chemistry letters 2016. link 5 Lin SL, Chang FL, Ho SY, Charoenkwan P, Wang KW, Huang HL. Predicting Neuroinflammation in Morphine Tolerance for Tolerance Therapy from Immunostaining Images of Rat Spinal Cord. PloS one 2015. link 6 Eisenach JC, Tong C, Curry R. Phase 1 safety assessment of intrathecal oxytocin. Anesthesiology 2015. link 7 Bai L, Zhai C, Han K, Li Z, Qian J, Jing Y et al.. Toll-like receptor 4-mediated nuclear factor-κB activation in spinal cord contributes to chronic morphine-induced analgesic tolerance and hyperalgesia in rats. Neuroscience bulletin 2014. link 8 Chiechio S, Copani A, De Petris L, Morales ME, Nicoletti F, Gereau RW. Transcriptional regulation of metabotropic glutamate receptor 2/3 expression by the NF-kappaB pathway in primary dorsal root ganglia neurons: a possible mechanism for the analgesic effect of L-acetylcarnitine. Molecular pain 2006. link 9 Seybold VS, McCarson KE, Mermelstein PG, Groth RD, Abrahams LG. Calcitonin gene-related peptide regulates expression of neurokinin1 receptors by rat spinal neurons. The Journal of neuroscience : the official journal of the Society for Neuroscience 2003. link 10 Inoue M, Mishina M, Ueda H. Enhanced nociception by exogenous and endogenous substance P given into the spinal cord in mice lacking NR(2)A/epsilon(1), an NMDA receptor subunit. British journal of pharmacology 2000. link 11 Malcangio M, Garrett NE, Cruwys S, Tomlinson DR. Nerve growth factor- and neurotrophin-3-induced changes in nociceptive threshold and the release of substance P from the rat isolated spinal cord. The Journal of neuroscience : the official journal of the Society for Neuroscience 1997. link 12 Otsuka M, Yanagisawa M. Effect of a tachykinin antagonist on a nociceptive reflex in the isolated spinal cord-tail preparation of the newborn rat. The Journal of physiology 1988. link 13 da Silva SEB, da Silva Moura JA, Branco Júnior JF, de Moraes Gomes PAT, de Paula SKS, Viana DCF et al.. Synthesis and . Current topics in medicinal chemistry 2024. link 14 Ben Othman A, Ben Ali R, Ben Akacha A, El May MV. Modulation of inflammatory mediators involved in the antinociceptive and anti-inflammatory effects of a new thioamide derivative: thiocyanoacetamide. Inflammopharmacology 2023. link 15 Zhang G, Tian C, Liang T, Chi H, Wu A, Li J et al.. The analgesic properties of Yu-Xue-Bi tablets in the inflammatory pain mice: By the inhibition of CCL3-mediated macrophage transmigration into the spinal cord. Journal of ethnopharmacology 2022. link 16 Arana-Argáez VE, Domínguez F, Moreno DA, Isiordia-Espinoza MA, Lara-Riegos JC, Ceballos-Góngora E et al.. Anti-inflammatory and antinociceptive effects of an ethanol extract from Senna septemtrionalis. Inflammopharmacology 2020. link 17 Chen J, Cong X, Zhan X, Zhou Z, Zheng W. Effects of Parecoxib on Pain Threshold and Inflammatory Factors IL-1β, IL-6 and TNF-𝜶 in Spinal Cord of Rats with Bone Cancer Pain. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2019. link 18 Ruan JP, Chen L, Ma ZL. Activation of spinal Extacellular Signal-Regulated Kinases and c-jun N-terminal kinase signaling pathways contributes to morphine-induced acute and chronic hyperalgesia in mice. Journal of cellular biochemistry 2019. link 19 Yagura S, Onimaru H, Kanzaki K, Izumizaki M. Inhibitory effects of eugenol on putative nociceptive response in spinal cord preparation isolated from neonatal rats. Experimental brain research 2018. link 20 Sasmita AO, Ling APK, Voon KGL, Koh RY, Wong YP. Madecassoside activates anti‑neuroinflammatory mechanisms by inhibiting lipopolysaccharide‑induced microglial inflammation. International journal of molecular medicine 2018. link 21 Chamaa F, Bitar L, Darwish B, Saade NE, Abou-Kheir W. Intracerebroventricular injections of endotoxin (ET) reduces hippocampal neurogenesis. Journal of neuroimmunology 2018. link 22 Donnerer J, Liebmann I. Upregulation of BDNF and Interleukin-1ß in rat spinal cord following noxious hind paw stimulation. Neuroscience letters 2018. link 23 Ye L, Xiao L, Yang SY, Duan JJ, Chen Y, Cui Y et al.. Cathepsin S in the spinal microglia contributes to remifentanil-induced hyperalgesia in rats. Neuroscience 2017. link 24 Egbe EO, Akumka DD, Adamu M, Mikail HG. Phytochemistry, Antinociceptive and Anti-inflammatory Actvities of Methanolic Leaves Extract of Lannea schimperi (Hoschst. Ex Rich) ENG. Recent patents on biotechnology 2016. link 25 Jeong YC, Son JS, Kwon YB. The spinal antinociceptive mechanism determined by systemic administration of BD1047 in zymosan-induced hyperalgesia in rats. Brain research bulletin 2015. link 26 Olajide OA, Kumar A, Velagapudi R, Okorji UP, Fiebich BL. Punicalagin inhibits neuroinflammation in LPS-activated rat primary microglia. Molecular nutrition & food research 2014. link 27 Ferrini F, Russo A, Salio C. Fos and pERK immunoreactivity in spinal cord slices: Comparative analysis of in vitro models for testing putative antinociceptive molecules. Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft 2014. link 28 Wei H, Saarnilehto M, Falck L, Viisanen H, Lasierra M, Koivisto A et al.. Spinal transient receptor potential ankyrin 1 channel induces mechanical hypersensitivity, increases cutaneous blood flow, and mediates the pronociceptive action of dynorphin A. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 2013. link 29 Khan S, Shehzad O, Chun J, Kim YS. Mechanism underlying anti-hyperalgesic and anti-allodynic properties of anomalin in both acute and chronic inflammatory pain models in mice through inhibition of NF-κB, MAPKs and CREB signaling cascades. European journal of pharmacology 2013. link 30 Block L, Björklund U, Westerlund A, Jörneberg P, Biber B, Hansson E. A new concept affecting restoration of inflammation-reactive astrocytes. Neuroscience 2013. link 31 Sun Y, Sahbaie P, Liang DY, Li WW, Li XQ, Shi XY et al.. Epigenetic regulation of spinal CXCR2 signaling in incisional hypersensitivity in mice. Anesthesiology 2013. link 32 Zhao YS, Zhang R, Xu Y, Cui Y, Liu YF, Song YB et al.. The role of glycine residues at the C-terminal peptide segment in antinociceptive activity: a molecular dynamics simulation. Journal of molecular modeling 2013. link 33 Qian GM, Pan GF, Guo JY. Anti-inflammatory and antinociceptive effects of cordymin, a peptide purified from the medicinal mushroom Cordyceps sinensis. Natural product research 2012. link 34 Vacca V, Marinelli S, Eleuteri C, Luvisetto S, Pavone F. Botulinum neurotoxin A enhances the analgesic effects on inflammatory pain and antagonizes tolerance induced by morphine in mice. Brain, behavior, and immunity 2012. link 35 Andreev YA, Vassilevski AA, Kozlov SA. Molecules to selectively target receptors for treatment of pain and neurogenic inflammation. Recent patents on inflammation & allergy drug discovery 2012. link 36 Fan L, Wang K, Shi Z, Die J, Wang C, Dang X. Tetramethylpyrazine protects spinal cord and reduces inflammation in a rat model of spinal cord ischemia-reperfusion injury. Journal of vascular surgery 2011. link 37 Watanabe C, Mizoguchi H, Yonezawa A, Sakurada S. Characterization of intrathecally administered hemokinin-1-induced nociceptive behaviors in mice. Peptides 2010. link 38 González-Rodríguez S, Hidalgo A, Baamonde A, Menéndez L. Involvement of Gi/o proteins and GIRK channels in the potentiation of morphine-induced spinal analgesia in acutely inflamed mice. Naunyn-Schmiedeberg's archives of pharmacology 2010. link 39 Pavone F, Luvisetto S, Marinelli S, Straface E, Fabbri A, Falzano L et al.. The Rac GTPase-activating bacterial protein toxin CNF1 induces analgesia up-regulating mu-opioid receptors. Pain 2009. link 40 Ma J, Hwang YK, Cho WH, Han SH, Hwang JK, Han JS. Macelignan attenuates activations of mitogen-activated protein kinases and nuclear factor kappa B induced by lipopolysaccharide in microglial cells. Biological & pharmaceutical bulletin 2009. link 41 Pan CH, Kim ES, Jung SH, Nho CW, Lee JK. Tectorigenin inhibits IFN-gamma/LPS-induced inflammatory responses in murine macrophage RAW 264.7 cells. Archives of pharmacal research 2008. link 42 Maranto J, Rappaport J, Datta PK. Regulation of complement component C3 in astrocytes by IL-1beta and morphine. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 2008. link 43 Park JS, Woo MS, Kim DH, Hyun JW, Kim WK, Lee JC et al.. Anti-inflammatory mechanisms of isoflavone metabolites in lipopolysaccharide-stimulated microglial cells. The Journal of pharmacology and experimental therapeutics 2007. link 44 Nikitin VP, Kozyrev SA. Transcription factor serum response factor is selectively involved in the mechanisms of long-term synapse-specific plasticity. Neuroscience and behavioral physiology 2007. link 45 Cury Y, Picolo G. Animal toxins as analgesics--an overview. Drug news & perspectives 2006. link 46 Suzuki M, Narita M, Narita M, Niikura K, Suzuki T. Chronic morphine treatment increases the expression of the neural cell adhesion molecule in the dorsal horn of the mouse spinal cord. Neuroscience letters 2006. link 47 Sycha T, Samal D, Chizh B, Lehr S, Gustorff B, Schnider P et al.. A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesthesia and analgesia 2006. link 48 Padwad Y, Ganju L, Jain M, Chanda S, Karan D, Kumar Banerjee P et al.. Effect of leaf extract of Seabuckthorn on lipopolysaccharide induced inflammatory response in murine macrophages. International immunopharmacology 2006. link 49 Cordero-Erausquin M, Pons S, Faure P, Changeux JP. Nicotine differentially activates inhibitory and excitatory neurons in the dorsal spinal cord. Pain 2004. link 50 Sakurada C, Sugiyama A, Nakayama M, Yonezawa A, Sakurada S, Tan-No K et al.. Antinociceptive effect of spinally injected L-NAME on the acute nociceptive response induced by low concentrations of formalin. Neurochemistry international 2001. link00110-8) 51 Yajima Y, Narita M, Tsuda M, Imai S, Kamei J, Nagase H et al.. Modulation of NMDA- and (+)TAN-67-induced nociception by GABA(B) receptors in the mouse spinal cord. Life sciences 2000. link00975-9) 52 Gilron I, Quirion R, Coderre TJ. Pre- versus postinjury effects of intravenous GABAergic anesthetics on formalin-induced Fos immunoreactivity in the rat spinal cord. Anesthesia and analgesia 1999. link 53 Song HK, Pan HL, Eisenach JC. Spinal nitric oxide mediates antinociception from intravenous morphine. Anesthesiology 1998. link 54 Gouardères C, Tafani JA, Zajac JM. Affinity of neuropeptide FF analogs to opioid receptors in the rat spinal cord. Peptides 1998. link00015-1) 55 Okano K, Kuraishi Y, Satoh M. Involvement of spinal substance P and excitatory amino acids in inflammatory hyperalgesia in rats. Japanese journal of pharmacology 1998. link 56 Watkins LR, McGorry M, Schwartz B, Sisk D, Wiertelak EP, Maier SF. Reversal of spinal cord non-opiate analgesia by conditioned anti-analgesia in the rat. Pain 1997. link03375-7) 57 Buritova J, Honoré P, Besson JM. Ketoprofen produces profound inhibition of spinal c-Fos protein expression resulting from an inflammatory stimulus but not from noxious heat. Pain 1996. link03138-7) 58 Stanfa L, Dickenson A. Spinal opioid systems in inflammation. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1995. link 59 Tölle TR, Schadrack J, Castro-Lopes JM, Evan G, Roques BP, Zieglgänsberger W. Effects of Kelatorphan and morphine before and after noxious stimulation on immediate-early gene expression in rat spinal cord neurons. Pain 1994. link90155-4) 60 Ceriani G, Macaluso A, Catania A, Lipton JM. Central neurogenic antiinflammatory action of alpha-MSH: modulation of peripheral inflammation induced by cytokines and other mediators of inflammation. Neuroendocrinology 1994. link 61 Shah S, Duttaroy A, Davis T, Yoburn BC. Spinal and supraspinal effects of pertussis toxin on opioid analgesia. Pharmacology, biochemistry, and behavior 1994. link90101-5) 62 Brune K. Spinal cord effects of antipyretic analgesics. Drugs 1994. link 63 Malmberg AB, Yaksh TL. Spinal nitric oxide synthesis inhibition blocks NMDA-induced thermal hyperalgesia and produces antinociception in the formalin test in rats. Pain 1993. link90028-N) 64 Garces YI, Rabito SF, Minshall RD, Sagen J. Lack of potent antinociceptive activity by substance P antagonist CP-96,345 in the rat spinal cord. Life sciences 1993. link90148-v) 65 Eide PK, Hole K. Interactions between serotonin and substance P in the spinal regulation of nociception. Brain research 1991. link91322-r) 66 Semion IZ, Nawrocka E, Słoń J, Tartar A, Obuchowicz E, Gołba K et al.. Antinociceptive action of the SP1-4 tetrapeptide and of some tuftsin analogs. Polish journal of pharmacology and pharmacy 1990. link 67 Jia M, Nelson PG. Opiate peptide receptor types on cultured mouse spinal neurons. Peptides 1987. link90023-4) 68 Przewłocki R, Costa T, Lang J, Herz A. Pertussis toxin abolishes the antinociception mediated by opioid receptors in rat spinal cord. European journal of pharmacology 1987. link90013-6)

Inflammation of spinal cord caused by toxin